ATE442861T1 - Gegen antikörper gerichtete photodynamische therapie - Google Patents
Gegen antikörper gerichtete photodynamische therapieInfo
- Publication number
- ATE442861T1 ATE442861T1 AT04718503T AT04718503T ATE442861T1 AT E442861 T1 ATE442861 T1 AT E442861T1 AT 04718503 T AT04718503 T AT 04718503T AT 04718503 T AT04718503 T AT 04718503T AT E442861 T1 ATE442861 T1 AT E442861T1
- Authority
- AT
- Austria
- Prior art keywords
- photodynamic therapy
- directed against
- therapy directed
- against antibodies
- photosensitizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45265503P | 2003-03-07 | 2003-03-07 | |
| PCT/US2004/006985 WO2004080284A2 (en) | 2003-03-07 | 2004-03-08 | Antibody-targeted photodynamic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442861T1 true ATE442861T1 (de) | 2009-10-15 |
Family
ID=32990667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04718503T ATE442861T1 (de) | 2003-03-07 | 2004-03-08 | Gegen antikörper gerichtete photodynamische therapie |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060231107A1 (de) |
| EP (1) | EP1605847B1 (de) |
| AT (1) | ATE442861T1 (de) |
| CA (1) | CA2530166A1 (de) |
| DE (1) | DE602004023183D1 (de) |
| WO (1) | WO2004080284A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117987A1 (en) * | 2004-06-01 | 2005-12-15 | Glazier Alan N | Antibody conjugates targeting to ocular proteins |
| GB0520436D0 (en) | 2005-10-07 | 2005-11-16 | Photobiotics Ltd | Biological materials and uses thereof |
| WO2007130465A2 (en) * | 2006-05-02 | 2007-11-15 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| US7465312B2 (en) * | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| US8034091B2 (en) | 2007-06-08 | 2011-10-11 | Laserix Sarl | Method for the ablation of cartilage tissue in a knee joint using indocyanine |
| WO2010069073A1 (en) | 2008-12-16 | 2010-06-24 | Qlt Inc. | Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature |
| EP2374825A1 (de) * | 2008-12-17 | 2011-10-12 | Keio University | Fotodynamisches therapeutikum mit anhäufung von zellspezifischen funktionen |
| JP2013518672A (ja) | 2010-02-01 | 2013-05-23 | モンテフィオーレ メディカル センター | 角膜コラーゲンの架橋のため、および眼の障害の治療のための方法およびデバイス |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| JP5963005B2 (ja) * | 2010-07-19 | 2016-08-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー |
| CA2811605A1 (en) * | 2010-09-16 | 2012-03-22 | Case Western Reserve University | Photodynamic therapy system, device and associated method of treatment |
| CN103739710B (zh) * | 2014-01-26 | 2015-12-09 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗vegf抗体及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2954463C (en) | 2014-08-08 | 2023-11-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photo-controlled removal of targets in vitro and in vivo |
| EP3331909B1 (de) | 2015-08-07 | 2026-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nahinfrarot-photoimmunotherapie (nir-pit) von suppressorzellen zur behandlung von krebs |
| EP3337514B8 (de) | 2015-08-18 | 2022-04-06 | Rakuten Medical, Inc. | Zusammensetzung aus einem konjugat mit einem phthalocyaninfarbstoff, der mit einem zielmollekel für fotoimmunotherapie verbunden ist |
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4684521A (en) * | 1982-12-08 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
| US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
| US4606118A (en) * | 1985-02-27 | 1986-08-19 | Medtronic, Inc. | Method of making a drug dispensing body |
| US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5093349A (en) * | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| US5177073A (en) * | 1988-09-30 | 1993-01-05 | Baylor Research Institute | Therapeutic compositions derived from photoactive compounds |
| US5053423A (en) * | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| US5238940A (en) * | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| US5589563A (en) * | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| US5405957A (en) * | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| US5454794A (en) * | 1993-10-15 | 1995-10-03 | Pdt Systems, Inc. | Steerable light diffusing catheter |
| US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| CA2215978A1 (en) * | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
| RU2066552C1 (ru) * | 1996-02-12 | 1996-09-20 | Товарищество с ограниченной ответственностью "Био Прогресс" | Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| WO1997035617A1 (en) * | 1996-03-26 | 1997-10-02 | Pharmacyclics, Inc. | Use of a texaphyrin in photodynamic therapy of pigment-related lesions |
| US6416960B1 (en) * | 1996-08-08 | 2002-07-09 | Prolume, Ltd. | Detection and visualization of neoplastic tissues and other tissues |
| US5877263A (en) * | 1996-11-25 | 1999-03-02 | Meadox Medicals, Inc. | Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
| US6043237A (en) * | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
| FR2765243B1 (fr) | 1997-06-30 | 1999-07-30 | Usinor | Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6364907B1 (en) * | 1998-10-09 | 2002-04-02 | Qlt Inc. | Method to prevent xenograft transplant rejection |
| DE69932733T2 (de) * | 1998-10-16 | 2007-08-16 | The General Hospital Corp., Boston | Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene |
| US6344050B1 (en) * | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| CA2395567A1 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
| US6180087B1 (en) * | 2000-01-18 | 2001-01-30 | Mallinckrodt Inc. | Tunable indocyanine dyes for biomedical applications |
| EP1997513B1 (de) * | 2000-02-10 | 2012-04-11 | Massachusetts Eye & Ear Infirmary | Kombinationen und Zubereitung zur Anwendung in PDT zur Behandlung von Augenleiden mit unerwünschter choriodaler Neovascularisation |
| US20020026945A1 (en) * | 2000-07-24 | 2002-03-07 | Gomer Charles J. | Enhancement of photodynamic therapy by anti-angiogenic treatment |
| AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| US8034803B2 (en) * | 2001-02-06 | 2011-10-11 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
| CA2445898A1 (en) * | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| HRP20040406A2 (en) * | 2001-11-09 | 2005-02-28 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| US6968234B2 (en) * | 2002-04-25 | 2005-11-22 | Medtronic, Inc. | Implantable medical device having biologically active polymeric casing |
-
2004
- 2004-03-08 WO PCT/US2004/006985 patent/WO2004080284A2/en not_active Ceased
- 2004-03-08 EP EP04718503A patent/EP1605847B1/de not_active Expired - Lifetime
- 2004-03-08 CA CA002530166A patent/CA2530166A1/en not_active Abandoned
- 2004-03-08 US US10/548,183 patent/US20060231107A1/en not_active Abandoned
- 2004-03-08 AT AT04718503T patent/ATE442861T1/de not_active IP Right Cessation
- 2004-03-08 DE DE602004023183T patent/DE602004023183D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2530166A1 (en) | 2004-09-23 |
| WO2004080284A3 (en) | 2004-10-21 |
| EP1605847A4 (de) | 2008-02-27 |
| WO2004080284A9 (en) | 2005-07-28 |
| DE602004023183D1 (de) | 2009-10-29 |
| EP1605847A2 (de) | 2005-12-21 |
| WO2004080284A2 (en) | 2004-09-23 |
| EP1605847B1 (de) | 2009-09-16 |
| US20060231107A1 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1605847A4 (de) | Gegen antikörper gerichtete photodynamische therapie | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
| DK1742644T3 (da) | Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin | |
| NO20054988D0 (no) | Preparater og metoder for behandling av cancer | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| DK1594542T3 (da) | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| TW200612918A (en) | Lonidamine analogs | |
| DK1558616T4 (da) | Meso-substituerede porphyriner | |
| CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| DE602005026313D1 (de) | Pharmazeutische formulierungen von decitabin | |
| BR0010702A (pt) | Novas quinonas como terapias de doenças | |
| NO20072543L (no) | Anti-cancer-behandling | |
| DK1276501T3 (da) | Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi | |
| NO20055390D0 (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
| DK1708693T3 (da) | Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf | |
| ITMI20041923A1 (it) | Sorgente luminosa per terapia fotodinamica con caratteristiche migliorate per l'implementazione dei protocolli terapeutici | |
| TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
| CY1117275T1 (el) | Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |